BMS and Exelixis' Opdivo/Cabometyx shows continued benefit in kidney cancer
BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer Combination also demonstrated benefit in sarcomatoid subgroup with poor prognoses Bristol Myers Squibb (BMS) and Exelixis have revealed new analyses from a phase 3 study of their Opdivo and Cabometyx combination in kidney cancer. The updated results come from the phase 3 CheckMate-9ER trial, which compared BMS’ checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ tyrosine kinase inhibitor (TKI) Cabometyx to Pfizer’s older drug Sutent (sunitinib) in the first-line treatment of advanced renal cell carcinoma (R...